We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III
Read MoreHide Full Article
Adamas Pharmaceuticals, Inc. announced positive data from the phase III study – EASE LID 3 – on its lead wholly owned candidate, ADS-5102 extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD). We expect investors to react positively to the news.
Data from the study demonstrated a statistically significant reduction in LID at 12 weeks in patients receiving ADS-5102, compared with placebo, as assessed by the Unified Dyskinesia Rating Scale (UDysRS). The candidate was safe and generally well tolerated. The study met its primary endpoint. Results were presented at the World Parkinson Congress in Portland.
In addition, Adamas Pharma announced positive post-hoc analysis of data from the EASE LID study on ADS-5102. Results from the study showed an improvement in activities of daily living (ADLs) in PD patients.
The company is presently conducting an open-label safety study – EASE LID 2 – which is open to patients from EASED, EASE LID and EASE LID 3, and LID patients who have undergone deep brain stimulation. Patients in the study will be followed for up to two years.
Meanwhile, Adamas Pharma expects to file a New Drug Application (NDA) for ADS-5102 for the treatment of LID later this year.
PD, a chronic progressive motor disorder, is said to impact 800,000 individuals in the U.S. Out of this, motor complications affect about 400,000 patients, and LID occurs in about 150,000 patients.
Successful development and commercialization of ADS-5102 will enable the company to capture a large share of the market, which currently has no approved drug in the indication.
Note that ADS-5102 is also being evaluated in a phase II study for the treatment of symptoms associated with multiple sclerosis in patients with walking impairment.
Going ahead, we expect investor focus to remain on further pipeline updates by the company.
Adamas Pharma currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III
Adamas Pharmaceuticals, Inc. announced positive data from the phase III study – EASE LID 3 – on its lead wholly owned candidate, ADS-5102 extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD). We expect investors to react positively to the news.
Data from the study demonstrated a statistically significant reduction in LID at 12 weeks in patients receiving ADS-5102, compared with placebo, as assessed by the Unified Dyskinesia Rating Scale (UDysRS). The candidate was safe and generally well tolerated. The study met its primary endpoint. Results were presented at the World Parkinson Congress in Portland.
In addition, Adamas Pharma announced positive post-hoc analysis of data from the EASE LID study on ADS-5102. Results from the study showed an improvement in activities of daily living (ADLs) in PD patients.
The company is presently conducting an open-label safety study – EASE LID 2 – which is open to patients from EASED, EASE LID and EASE LID 3, and LID patients who have undergone deep brain stimulation. Patients in the study will be followed for up to two years.
Meanwhile, Adamas Pharma expects to file a New Drug Application (NDA) for ADS-5102 for the treatment of LID later this year.
ADAMAS PHARMA Price
ADAMAS PHARMA Price | ADAMAS PHARMA Quote
PD, a chronic progressive motor disorder, is said to impact 800,000 individuals in the U.S. Out of this, motor complications affect about 400,000 patients, and LID occurs in about 150,000 patients.
Successful development and commercialization of ADS-5102 will enable the company to capture a large share of the market, which currently has no approved drug in the indication.
Note that ADS-5102 is also being evaluated in a phase II study for the treatment of symptoms associated with multiple sclerosis in patients with walking impairment.
Going ahead, we expect investor focus to remain on further pipeline updates by the company.
Adamas Pharma currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>